NCT03081741 is a clinical trial in Lung Neoplasms, sponsored by Shenzhen Gene Health Bio Tech Co., Ltd..

Who is sponsoring NCT03081741?

NCT03081741 is sponsored by Shenzhen Gene Health Bio Tech Co., Ltd..

What condition does NCT03081741 study?

NCT03081741 studies Lung Neoplasms.

Is NCT03081741 still recruiting?

NCT03081741 is currently status unknown. Last updated 23 May 2017.

Last reviewed 2017-05-23 · How we verify

NCT03081741

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Circulating Tumor DNA in Surgical Lung Cancer Patients

Status unknown Last updated 23 May 2017

What this trial tests

trial in Lung Neoplasms in 500 participants. Status unknown.

Timeline

3 May 2017

Primary endpoint
1 December 2017

18 March 2020

Quick facts

Lead sponsor	Shenzhen Gene Health Bio Tech Co., Ltd.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	3 May 2017
Primary completion	1 December 2017
Estimated completion	18 March 2020
Sites	1 location across China

Conditions studied

Lung Neoplasms — all drugs for Lung Neoplasms →

Sponsor

Shenzhen Gene Health Bio Tech Co., Ltd.

Who can join

Adults 18 to 80, any sex, with Lung Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Conduct a prospective study to detect the change of ctDNA of surgical lung cancer patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.
Peng M, Xie Y, Li X, Qian Y, et al · · 2019 · cited 26× · PMID 30981987 · DOI 10.1136/jmedgenet-2018-105825
Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues.
Wu X, Zhu L, Ma PC. · · 2018 · cited 17× · PMID 30231325 · DOI 10.1200/edbk_199767

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03081741 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Gene Health Bio Tech Co., Ltd.
Last refreshed: 23 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03081741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing